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Aim: There are a considerable number of patients with non-
obese non-alcoholic fatty liver disease (NAFLD). However, the
clinical characteristics of non-obese NAFLD is not fully under-
stood. We investigated genetic and other clinical parameters
in non-obese and obese NAFLD.
Methods: The single nucleotide polymorphism rs738409 in the
patatin-like phospholipase 3 gene (PNPLA3) was genotyped by
the Invader assay in 540 NAFLD patients (134 non-obese and
406 obese) and 1012 control subjects (782 non-obese and 230
obese). All NAFLD patients underwent liver biopsy. Odds ratios
were calculated by multiple logistic regression analysis using
age, sex, body mass index (BMI), type 2 diabetes mellitus
(T2DM) and rs738409 genotype as explanatory variables.
Results: Non-obese NAFLD subjects had a higher rs738409 GG
genotype than obese NAFLD. Multiple logistic regression
analysis indicated that the odds ratios of T2DM and rs738409
GG genotype for NAFLD were higher in non-obese than in obese
groups. In non-obese NAFLD, rs738409 GG genotypewas associ-
ated with lobular inﬂammation, hepatocyte ballooning and
NAFLD activity score. In obese NAFLD, BMI and T2DM but not
rs738409 GG genotype were associated with severity of
histology.
Conclusion: We demonstrated that the risk factors for the
development and progression of NAFLDwere different between
non-obese and obese patients and that PNPLA3 rs738409 was
strongly associated with the development and progression of
non-obese NAFLD.
Key words: non-alcoholic fatty liver disease, non-obese non-
alcoholic fatty liver disease, PNPLA3, type 2 diabetes mellitus
INTRODUCTION
NON-ALCOHOLIC FATTY LIVER disease (NAFLD) isnow considered as an important health concern.1,2
NAFLD is a hepatic phenotype of metabolic syndrome
and is a major form of chronic liver disease except for
alcoholic hepatitis.3 NAFLD is a clinical and pathological
concept that encompasses a disease spectrum ranging
from non-alcoholic fatty liver (NAFL) to non-alcoholic
steatohepatitis (NASH), cirrhosis and hepatocellular
carcinoma.4
Various risk factors for the development of NAFLD
have been reported. One factor is obesity and the num-
ber of NAFLD patients has increased in parallel with
the rising prevalence of obesity.5,6 NAFLD has been
observed to be 4.6-times higher in obese than in non-
obese subjects.7 More than 84% of obese patients who
underwent bariatric surgery have NAFLD and 2–12%
have fibrosis or cirrhosis.8–11 Type 2 diabetes mellitus
(T2DM) is also an important risk factor for NAFLD,
and one-third to one-half of T2DM patients have
NAFLD.12 High serum triglycerides and low high-
density lipoprotein (HDL) cholesterol levels are com-
monly observed in patients with NAFLD.13
Genetic factors as well as environmental factors are
important in the development of NAFLD.14–17 Recent
genome-wide association studies (GWAS) have identi-
fied that single nucleotide polymorphisms (SNP) in
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the patatin-like phospholipase domain containing 3
(PNPLA3) were the most important genetic factors asso-
ciated with NAFLD.18–22 We reported that the risk allele
(G allele) of rs738409 in PNPLA3 is associated with
NAFLD in the Japanese population.23 We performed
targeted next-generation sequencing of the genomic
region containing PNPLA3 rs738409 and reported that
polymorphisms in PNPLA3 were associated with the
development and progression of NAFLD.24 A meta-
analysis revealed that the G allele was associated with
increased aminotransferase and severity of NAFLD in
various ethnic groups.25
Although many NAFLD patients are obese, there is a
considerable number of non-obese NAFLD patients in
Asia. According to previous reports in Japan, the preva-
lence of non-obese NAFLD was 11.1–18.4% of all
NAFLD patients.5,26,27 Studies in other Asian countries
have also reported the prevalence of non-obese
NAFLD.28,29 Even though many studies have shown
an association between NAFLD and obesity, it remains
unclear how patients without obesity develop NAFLD.
In addition, not only obese NAFLD but also non-obese
NAFLD patients have an increased risk of cardiovascu-
lar disease.30 Therefore, it is important to understand
the clinical and pathological conditions of non-obese
NAFLD. At present, the clinical characteristics of
non-obese NAFLD are not fully understood, and it is
assumed that some risk factors other than obesity
would affect the development of non-obese NAFLD.
In this study, we investigated the genetic factors in ad-
dition to other clinical parameters in non-obese and
obese NAFLD.
METHODS
Subjects
THE ENTIRE STUDY was conducted following guide-lines of the Declaration of Helsinki and was approved
by the Ethics Committees of Osaka University, Yokohama
City University, Hiroshima University and Kurume
University. Written informed consent was obtained from
each participant.
The sample size of NAFLD patients and control
subjects were 540 and 1012, respectively, and both
groups were recruited from our previous study.31,32
Briefly, NAFLD and control subjects were enrolled
from Yokohama City University Hospital, Hiroshima
University Hospital and Kurume University Hospital.
Control subjects (general population) were Japanese
volunteers undergoing medical examinations for com-
mon disease screening. Patients with the following
diseases were excluded: infectious hepatitis (hepatitis
B and C, Epstein–Barr virus infection), autoimmune
hepatitis, primary biliary cirrhosis, sclerosing cholangitis,
hemochromatosis, α1-antitrypsin deficiency, Wilson’s
disease, drug-induced hepatitis, alcoholic hepatitis
and excessive alcohol consumption (present or past daily
consumption of >20 g/day alcohol). No NAFLD patient
had clinical evidence of hepatic decompensation, such
as hepatic encephalopathy, ascites, variceal bleeding or
a serum bilirubin level greater than twice the upper limit
of normal.
Non-alcoholic fatty liver disease patients and control
subjects were divided into groups of non-obese (body
mass index [BMI] <25 kg/m2) or obese (BMI ≥25 kg/m2).
Obesity was diagnosed according to the World Health
Organization (WHO) Asia–Pacific guidelines.33
Anthropometric and laboratory evaluation
Bodymass index was calculated as bodyweight (kg) divided
by height (m) squared. Venous blood samples were
obtained from subjects after an overnight fast (12 h) for
the measurement of fasting plasma glucose (FPG), serum
aspartate transaminase (AST), alanine transaminase (ALT),
hemoglobin A1c (HbA1c), insulin, total cholesterol, triglyc-
erides and HDL cholesterol. The Homeostasis Model of
Assessment – Insulin Resistance (HOMA-IR) was used as
an indicator of insulin resistance and was calculated as
follows: HOMA-IR=plasma glucose (mg/dL)× insulin
(μU/mL) / 405. All laboratory biochemical parameters were
measured in a conventional automated analyzer.
Patients with fasting plasma glucose of 126 mg/dL or
more, HbA1c of 6.5% or more, and/or current use of
antidiabetic medications were diagnosed with T2DM
according to the criteria by the committee of the Japan
Diabetes Society.34
Histological evaluation
All NAFLD patients underwent a percutaneous liver biopsy
for the purpose of diagnosing and staging of NASH. Liver
biopsy tissues were stained with hematoxylin–eosin,
Masson’s trichrome and reticulin silver stain. Fatty liver
was defined as the presence of more than 5% steatosis.
The severity of steatosis, features of NASH, fibrosis and
NAFLD activity score (NAS) were assessed according to
Kleiner et al.35 and Brunt et al..36
DNA preparation and SNP genotyping
Genomic DNA was extracted using Genomix (Talent,
Trieste, Italy) from blood samples collected from
each subject. Invader probe (Third Wave Technologies,
Madison, WI, USA) was constructed for rs738409 and
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genotyped. The success rate of this assay was more
than 99.0%.
Statistical analysis
Simple comparisons of the clinical data between
two groups were carried out using the Mann–Whitney
U-test. Simple comparisons of the clinical data between
the different genotypes were carried out using the
Kruskal–Wallis test. We used the recessive model:
homozygosity with the rs738409 risk allele GG, which
was coded as 1, and GC and CC coded as 0. Multiple
linear regression analyses were performed to test the
independent effect of explanatory variables (age, sex,
BMI, T2DM and rs738409 genotype) on levels of triglyc-
erides, AST and ALT. Odds ratios (OR) were calculated
by multiple logistic regression analysis using age, sex,
BMI, T2DM and rs738409 genotype as explanatory
variables. P< 0.05 was considered significant. All statis-
tical analyses were carried out using the software R
(http://www.r-project.org/).
RESULTS
Characteristics of non-obese and obese NAFLD
THE CLINICAL CHARACTERISTICS of the non-obeseand obese NAFLD groups and control subjects are
shown in Table 1. Non-obese NAFLD subjects had higher
rs738409 GG genotype than obese NAFLD (47.8% vs
36.5%, respectively; P=0.02). The GG genotype frequency
of rs738409 was comparable between non-obese and
obese control subjects (19.9% vs 18.7%, respectively;
P=0.67). The numbers of female subjects with NAFLD
and the control were higher in the non-obesity group than
in the obesity group. Non-obese NAFLD patients were
older than obese NAFLD patients and non-obese control
subjects were younger than obese control subjects. The
percentage of T2DM was higher in obese NAFLD patients
than in non-obese NAFLD patients, but not significantly
(36.5% vs 32.9%, respectively; P=0.51). The number of
T2DM in obese control subjects was significantly more
than non-obese control subjects (15.7% vs 4.2%, respec-
tively; P=3.7×10–9). FPG, insulin and HOMA-IR were
Table 1 Clinical characteristics between NAFLD and control subjects with different BMI
NAFLD Control
Non-obese Obese P Non-obese Obese P
n 134 406 – 782 230 –
CC/CG/GG (n) 23/47/64 78/180/148 0.067 237/389/156 63/124/43 0.75
GG genotype frequency (%) 47.8% 36.5% 0.02 19.9% 18.7% 0.67
T2DM (%) 44 (32.9%) 148 (36.5%) 0.51 33 (4.2) 36 (15.7) 3.7 × 10–9
Male/female (n) 57/77 228/178 0.0083 362/420 138/92 0.00034
Age (years) 56.6 ± 13.6 48.5± 13.9 7.6 × 10–9 51.7± 15.7 57.8± 12.6 2.4 × 10–6
BMI (kg/m2) 22.8 ± 1.5 29.8± 4.5 1.4 × 10–67 21.4± 2.1 27.0± 2.0 7.3 × 10–118
FPG (mg/dL) 114.4 ± 32.4 119.9 ± 37.2 0.024 96.2± 18.3 104.9 ± 19.8 5.7 × 10–15
HbA1c (%) 6.3 ± 1.4 6.4 ± 1.2 0.30 5.5 ± 0.6 5.7 ± 0.7 1.4 × 10
–8
Insulin (mU/mL) 11.4 ± 13.1 16.9± 11.5 9.8 × ×10–14 – – –
HOMA-IR 3.4 ± 4.9 5.0 ± 4.1 2.9 × 10–13 – – –
Total cholesterol (mg/dL) 213.3 ± 39.6 212.1 ± 39.3 0.67 205.5 ± 36.2 218.8 ± 34.4 1.0 × 10–7
Triglycerides (mg/dL) 144.3 ± 69.2 174.4 ± 113.7 0.0016 99.4± 63.9 145.7 ± 137.8 3.7 × 10–16
HDL cholesterol (mg/dL) 57.4 ± 14.4 51.4± 14.7 5.5 × 10–7 64.5± 15.4 56.7± 14.3 6.1 × 10–12
AST (IU/L) 47.1 ± 31.4 51.1± 29.3 0.0052 22.1± 9.4 26.0± 12.2 1.8 × 10–6
ALT (IU/L) 70.7 ± 54.5 84.3± 56.5 0.00037 18.2± 8.5 27.2± 17.1 7.0 × 10–16
Steatosis grade (0–3) 1.4 ± 0.6 1.7 ± 0.7 0.00078 – – –
Lobular inﬂammation (0–3) 1.1 ± 0.7 1.3 ± 0.7 0.0028 – – –
Hepatocyte ballooning (0–2) 1.0 ± 0.8 1.2 ± 0.6 0.0046 – – –
NAS (0–8) 3.5 ± 1.6 4.2 ± 1.5 7.4 × 10–5 – – –
Fibrosis stage (0–4) 1.6 ± 1.1 1.7 ± 1.0 0.096 – – –
Data are represented as the mean± standard deviation.
P-values for comparison of the clinical data between two groups were obtained by theMann–WhitneyU-test, and ratios were analyzed by χ2-test.
ALT, alanine transaminase; AST, aspartate transaminase; BMI, bodymass index; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high-
density lipoprotein; HOMA-IR, Homeostasis Model of Assessment – Insulin Resistance; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD
activity score; T2DM, type 2 diabetes mellitus.
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lower in non-obese NAFLD than in obese NAFLD patients.
FPG and HbA1c were lower in non-obese controls than in
obese control subjects. Triglycerides and HDL cholesterol
levels were lower in non-obese NAFLD than in obese
NAFLD patients. Total cholesterol, triglycerides and HDL
cholesterol levels were lower in non-obese controls than
in obese control subjects. AST and ALT levels were lower
in non-obese NAFLD and controls than in obese NAFLD
patients and control subjects. Steatosis grade, lobular
inflammation, hepatocyte ballooning and NAS were
significantly lower in non-obese NAFLD compared with
obese NAFLD patients. There was no significant difference
in fibrosis stage between non-obese and obese NAFLD
patients.
Associations of BMI, T2DM and rs738409 with
non-obese and obese NAFLD patients
We performed multiple logistic analysis to investigate the
effect of BMI, T2DM and rs738409 GG genotype on
NAFLD with or without obesity adjusted for age and sex
(Table 2). BMI, T2DM and rs738409 GG genotype were
strongly associated with NAFLD both in non-obese and
obese groups. The OR of T2DM and rs738409 GG geno-
type were higher in non-obese than those in obese groups
(T2DM, 11.16 vs. 3.41, respectively; rs738409 GG geno-
type, 4.15 vs. 2.76, respectively).
Association of BMI, T2DM and rs738409 with
the levels of triglycerides, AST, ALT and
histological severity in non-obese and obese
NAFLD
The clinical characteristics between the different genotypes
of rs738409 in non-obese and obese NAFLD patients are
shown in Table 3. Triglyceride levels were lower in patients
with rs738409 GG genotype than patients with rs738409
CC+CG genotypes in obese NAFLD. AST and ALT levels
were higher in patients with rs738409 GG genotype than
patients with rs738409 CC+CG genotypes in both non-
obese and obese NAFLD. In non-obese NAFLD, lobular
inflammation, hepatocyte ballooning, NAS and fibrosis
were higher in patients with rs738409 GG genotype than
patients with rs738409 CC+CG genotypes. In obese
NAFLD, steatosis and NAS were higher in patients with
rs738409 GG genotype than patients with rs738409 CC
+CG genotypes.
Multiple linear regression analysis was performed to
show the effect of BMI, T2DM and rs738409 on the levels
of triglycerides, AST and ALT (Table 4). Multiple logistic
analyses were performed to evaluate the effect of BMI,
T2DM and rs738409 on the histological severity after
adjustment for age and sex (Table 5). There were no signif-
icant associations of triglyceride levels with BMI, T2DM
and rs738409 GG genotype in both non-obese and obese
NAFLD. In non-obese NAFLD, BMI was significantly
associated with increases in AST and ALT levels (AST,
P=0.00021; ALT, P=0.0017). In obese NAFLD, the
presence of T2DM was significantly associated with
increased levels of AST and ALT (AST, P=0.00059; ALT,
P=0.0026). In non-obese and obese NAFLD, rs738409
GG genotype was significantly associated with increases
in levels of AST (P=0.00016 and P=0.0064, respectively)
and ALT (P=0.0009 and P=8.4×10–5, respectively).
Body mass index was associated with a higher steatosis
grade in both non-obese (P=0.049) and obese NAFLD
(P=0.018). GG genotype of rs738409 was also associated
with the steatosis grade in obese NAFLD (P=0.0048). In
non-obese NAFLD, rs738409 GG genotype was associated
with lobular inflammation (P=0.0055), hepatocyte
ballooning (P=0.031) and NAS (P=0.031). In obese
NAFLD, BMI and T2DM but not rs738409 GG genotype
were associated with the severity of histology. There was
no association of fibrosis with BMI, T2DM and rs738409
GG genotype in both non-obese and obese NAFLD.
DISCUSSION
PREVIOUS STUDIES HAVE reported that an increase inbodyweight, triglyceride levels and PNPLA3 rs738409
were risk factors for the development of non-obese
Table 2 Multiple logistic analysis for pathogenesis of NAFLD
Risk factor
Non-obese Obese
Adjusted OR (95% CI) P Adjusted OR (95% CI) P
BMI 1.57 (1.37–1.79) 2.3 × 10–11 1.33 (1.22–1.45) 9.4 × 10–11
T2DM 11.16 (6.27–19.86) 2.4 × 10–16 3.41 (2.14–5.44) 2.5 × 10–7
rs738409 GG genotype 4.15 (2.68–6.43) 2.0 × 10–10 2.76 (1.77–4.31) 8.3 × 10–6
The OR was adjusted for age and sex.
BMI, body mass index; CI, conﬁdence interval; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; T2DM, type 2 diabetes mellitus.
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NAFLD.37–41 In these reports, NAFLD was diagnosed by
abdominal ultrasound or proton-magnetic response
spectroscopy, but our study performed liver biopsies in
all NAFLD patients. Our study indicated that bodyweight
change, the presence of T2DM and rs738409 GG genotype
were the risk factors for development of NAFLD in both
non-obese and obese patients. Both T2DM and rs738409
GG genotype were strongly associated with non-obese
Table 3 Clinical characteristics of non-obese and obese NAFLD subjects with different PNPLA3 genotypes
Non-obese NAFLD Obese NAFLD
rs738409 genotypes
P
rs738409 genotypes
PCC+CG GG CC+CG GG
n 70 64 – 258 148 –
T2DM (%) 25 (35.7%) 19 (29.7%) 0.58 93 (36.0%) 55 (37.1%) 0.91
Male/female (n) 30/40 27/37 1.00 157/101 71/77 0.016
Age (years) 55.5± 12.7 57.8± 14.5 0.16 47.6± 13.7 50.1± 14.2 0.10
BMI (kg/m2) 22.9± 1.5 22.8± 1.5 0.71 29.7 ± 3.9 29.8± 5.3 0.41
FPG (mg/dL) 116.8 ± 33.8 111.9 ± 30.9 0.13 118.2 ± 34.2 122.7 ± 41.9 0.73
HbA1c (%) 6.5 ± 1.6 6.2 ± 1.1 0.31 6.4 ± 1.2 6.4 ± 1.3 0.57
Insulin (mU/mL) 9.6 ± 4.8 13.6± 18.3 0.15 16.7± 10.2 17.3± 13.5 0.69
HOMA-IR 2.9 ± 2.0 4.1 ± 6.9 0.66 4.9 ± 3.4 5.3 ± 5.3 0.65
Total cholesterol (mg/dL) 211.3 ± 37.7 215.5 ± 41.7 0.71 210.4 ± 38.2 214.9 ± 40.9 0.27
Triglycerides (mg/dL) 148.3 ± 74.9 140± 62.7 0.49 184.3 ± 130 157.3 ± 75 0.034
HDL cholesterol (mg/dL) 56.9± 13.4 58± 15.4 0.93 50.4± 14.8 53.1± 14.3 0.11
AST (IU/L) 38.1± 19.3 57.1± 38.5 0.0058 48.2± 30.1 56.2± 27.1 0.00015
ALT (IU/L) 58.3± 34.7 84.3± 67.8 0.019 78.1± 53.5 95.2± 60.1 0.0011
Steatosis grade (0–3) 1.4 ± 0.6 1.5 ± 0.7 0.81 1.6 ± 0.7 1.8 ± 0.8 0.0099
Lobular inﬂammation (0–3) 0.9 ± 0.7 1.3 ± 0.7 0.0019 1.3 ± 0.7 1.4 ± 0.7 0.26
Hepatocyte ballooning (0–2) 0.8 ± 0.8 1.1 ± 0.7 0.025 1.1 ± 0.6 1.2 ± 0.6 0.12
NAS (0–8) 3.1 ± 1.5 3.9 ± 1.6 0.0062 4.0 ± 1.5 4.4 ± 1.5 0.0073
Fibrosis stage (0–4) 1.4 ± 1.1 1.8 ± 1.1 0.046 1.7 ± 1.0 1.8 ± 1.0 0.17
Data are represented as the mean± standard deviation.
P-values for comparison of the clinical data between two groups were obtained by theMann–WhitneyU-test, and ratios were analyzed by χ2-test.
ALT, alanine transaminase; AST, aspartate transaminase; BMI, bodymass index; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high-
density lipoprotein; HOMA-IR, Homeostasis Model of Assessment – Insulin Resistance; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD
activity score; T2DM, type 2 diabetes mellitus.
Table 4 Multiple linear regression analysis for triglycerides, AST, and ALT
Explanatory variable Independent variable
Non-obese NAFLD Obese NAFLD
β SE P β SE P
Triglycerides BMI 3.617 4.100 0.38 2.447 1.317 0.064
T2DM 9.784 13.498 0.47 20.756 11.877 0.081
rs738409 GG genotype 7.237 12.110 0.55 20.375 11.528 0.078
AST BMI 6.429 1.683 0.00021 0.505 0.338 0.14
T2DM 1.374 5.542 0.80 10.561 3.050 0.00059
rs738409 GG genotype 19.309 4.972 0.00016 8.114 2.960 0.0064
ALT BMI 9.515 2.970 0.0017 0.601 0.613 0.33
T2DM 9.772 9.777 0.32 16.779 5.527 0.0026
rs738409 GG genotype 29.830 8.771 0.00090 21.312 5.365 8.4 × 10–5
Age and sex were adjusted.
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; NAFLD, non-alcoholic fatty liver disease; SE, standard error;
T2DM, type 2 diabetes mellitus.
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NAFLD. GG genotype of rs738409 was determined to be a
risk factor for the histological activity in non-obese
NAFLD. In obese NAFLD, an increase in BMI and the
presence of T2DM were associated with hepatic histology.
The present data suggested that the risk factors for the
development and progression of NAFLD would be differ-
ent between non-obese and obese patients. This study is
the first known report indicating the importance of SNP
rs738409 in the development and progression of non-
obese NAFLD.
In different ethnic groups, it has been reported that the
frequencies of the risk allele (G-allele) of rs738409 is
17% in African Americans, 23% in European descendants
and 49% in the Hispanic population.18,42 Its frequency in
the Japanese was 45% and, therefore, higher than the
African and European descendant populations. Therefore,
Japanese subjects with the rs738409 GG genotype would
be more susceptible to the development of NAFLD even
if they are lean.
The rs738409 GG genotype was not associated with the
fibrosis stage in non-obese and obese NAFLD, which
confirms the result of a previous report.43 Therefore, other
factors must be associated with the progression of fibrosis.
One possibility is epigenetics. We recently reported that
NAFLD patients with advanced fibrosis stage showed
hypermethylation of CpG99 in the PNPLA3 gene and a
lower expression of PNPLA3 compared with those with
the mild fibrosis stage. This phenomenon was prominent
in NAFLD patients with the rs738409 GG genotype.44
Thus, investigation of the epigenetic factors as well as
genetic factors would be necessary to elucidate the risks
for the progression of hepatic fibrosis in non-obese and
obese NAFLD patients.
The rs738409 GG genotype affected the AST and ALT
levels in both non-obese and obese NAFLD, confirming
the previous meta-analysis report.45 In addition to
rs738409 GG genotype, the increase of BMI in non-obese
NAFLD and the presence of T2DM in obese NAFLD were
associated with increased AST and ALT. The factors associ-
ated with AST and ALT were different in non-obese and
obese NAFLD, which suggests different pathogeneses
in non-obese and obese NAFLD. The association of
rs738409 with triglyceride levels is controversial46,47 be-
cause we found that the triglyceride level was not affected
by the rs738409 GG genotype in non-obese and obese
NAFLD.
There are several limitations in our study. First, we did
not evaluate lifestyle factors, such as calorie intake and
exercise. Second, patient selection bias could also have
existed, because liver biopsy might have been considered
for NAFLD patients who were likely to have NASH. Third,
our study was cross-sectional study. So, we did not evalu-
ate weight change by treatment intervention or weight gain
of 10 kg or more after the age of 20 years which is a risk
factor reported by Nishioji et al.41 Furthermore, the
number of non-obese NAFLD was relatively small, but
Table 5 Multiple logistic analysis for severity of histological grade and ﬁbrosis stage
Explanatory variable Risk factor
Non-obese NAFLD Obese NAFLD
Adjusted OR (95% CI) P Adjusted OR (95% CI) P
Steatosis (0/1 vs 2/3) BMI 1.32 (1.00–1.73) 0.049 1.07 (1.01–1.13) 0.018
T2DM 1.19 (0.51–2.76) 0.69 1.42 (0.91–2.20) 0.12
rs738409 GG genotype 1.17 (0.55–2.48) 0.69 1.86 (1.21–2.86) 0.0048
Lobular inﬂammation(0/1 vs. 2/3) BMI 1.33 (0.98–1.81) 0.069 1.01 (0.96–1.06) 0.64
T2DM 1.42 (0.58–3.52) 0.44 1.78 (1.16–2.75) 0.0089
rs738409 GG genotype 3.37 (1.43–7.96) 0.0055 0.99 (0.65–1.53) 0.98
Hepatocyte ballooning (0 vs 1/2) BMI 1.24 (0.95–1.62) 0.12 1.19 (1.06–1.34) 0.0027
T2DM 1.51 (0.60–3.82) 0.38 2.00 (0.95–4.19) 0.068
rs738409 GG genotype 2.51 (1.09–5.76) 0.031 1.46 (0.75–2.84) 0.26
NAS(0–4 vs 5–8) BMI 1.43 (1.06–1.94) 0.020 1.06 (1.01–1.12) 0.023
T2DM 1.39 (0.58–3.37) 0.46 2.18 (1.39–3.42) 0.00069
rs738409 GG genotype 2.42 (1.09–5.40) 0.031 1.55 (1.00–2.40) 0.051
Fibrosis (0/1/2 vs 3/4) BMI 1.39 (0.99–1.94) 0.054 1.03 (0.98–1.09) 0.28
T2DM 1.02 (0.40–2.62) 0.96 1.53 (0.95–2.46) 0.081
rs738409 GG genotype 1.76 (0.72–4.29) 0.21 1.35 (0.84–2.17) 0.21
The OR was adjusted for age and sex.
BMI, body mass index; CI, conﬁdence interval; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; T2DM, type 2 diabetes mellitus; NAS,
NAFLD activity score.
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our data suggest that the clinical aspects of NAFLD are
different between non-obese and obese patients. Further
investigation is necessary to elucidate the differences
between non-obese and obese NAFLD.
In summary, we demonstrated that the risk factors for
the development and progression of NAFLDwere different
between non-obese and obese patients and that PNPLA3
rs738409 was strongly associated with the development
and progression of non-obese NAFLD.
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Abstract
Background & Aims
In recent years, nonalcoholic steatohepatitis (NASH) has become a considerable health-
care burden worldwide. Pathogenesis of NASH is associated with type 2 diabetes mellitus
(T2DM) and insulin resistance. However, a specific drug to treat NASH is lacking. We inves-
tigated the effect of the selective sodium glucose cotransporter 2 inhibitor (SGLT2I) ipragli-
flozin on NASH in mice.
Methods
We used the Amylin liver NASH model (AMLN), which is a diet-induced model of NASH that
results in obesity and T2DM. AMLN mice were fed an AMLN diet for 20 weeks. SGLT2I
mice were fed an AMLN diet for 12 weeks and an AMLN diet with 40 mg ipragliflozin/kg for 8
weeks.
Results
AMLN mice showed steatosis, inflammation, and fibrosis in the liver as well as obesity and
insulin resistance, features that are recognized in human NASH. Ipragliflozin improved insu-
lin resistance and liver injury. Ipragliflozin decreased serum levels of free fatty acids, hepatic
lipid content, the number of apoptotic cells, and areas of fibrosis; it also increased lipid out-
flow from the liver.
Conclusions
Ipragliflozin improved the pathogenesis of NASH by reducing insulin resistance and lipotoxi-
city in NASH-model mice. Our results suggest that ipragliflozin has a therapeutic effect on
NASH with T2DM.
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Introduction
In recent decades, the metabolic syndrome has become increasingly prevalent and the inci-
dence of nonalcoholic fatty liver disease (NAFLD) has also increased [1–3]. NAFLD is associ-
ated with the metabolic syndrome [4–7]. NAFLD is a major form of chronic liver disease not
associated with significant consumption of alcohol. NAFLD is a clinical and pathologic term
describing a disease spectrum ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic
steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma [8]. Obesity and type 2 diabe-
tes mellitus (T2DM) are important risk factors for NAFLD. In the obese population, the preva-
lence of NAFLD is 4.6-times higher than that in normal individuals [9]. Among individuals
with DM, 33–50% of patients have NAFLD [10]. The common feature between T2DM and
NAFLD is insulin resistance [11–13]. The insulin-sensitizing agent pioglitazone has a beneficial
effect upon NASH, but its efficacy and safety in long-term studies have not been confirmed
[14]. Effective drug therapy for NASH has not been established.
Sodium glucose cotransporter 2 inhibitors (SGLT2Is) have been developed for T2DM treat-
ment. SGLT2Is prevent the reabsorption of glucose filtered by glomeruli and increase urinary
excretion of glucose [15–17]. Ipragliflozin is a selective inhibitor of SGLT2 that is orally admin-
istered. Ipragliflozin decreases blood levels of glucose and hemoglobin (Hb)A1c and improves
insulin resistance in T2DM patients and in several models of DM [18–23]. In addition, ipragli-
flozin has been shown to improve dyslipidemia and liver steatosis in streptozotocin–nicotin-
amide-induced T2DMmice fed a high-fat diet [21]. These mice were obese and had insulin
resistance and fatty liver, but did not have steatohepatitis or fibrosis. Hayashizaki-Someya et al.
[24] reported that ipragliflozin has a prophylactic effect on hepatic fibrosis in rats fed a cho-
line-deficient L-amino acid-defined (CDAA) diet. Mice fed a CDAA diet are used frequently as
a nutritional model of NASH. A CDAA diet induces an elevation in aminotransferase levels
and histologic changes characterized by steatosis, inflammation, hepatocyte necrosis, and tissue
fibrosis [25]. However, this model does not express obesity and insulin resistance, which are
features of NASH in humans. When investigating if ipragliflozin has a therapeutic effect upon
NASH, the model employed must be similar to NASH seen in humans.
We investigated the effect of ipragliflozin upon NASH in the Amylin liver NASH model
(AMLN). AMLN is a dietary model of NASH that expresses obesity, insulin resistance, and the
three stages of NAFLD (steatosis, steatohepatitis with fibrosis, and cirrhosis) [26].
Materials and Methods
Drugs and diets
Ipragliflozin L-proline was obtained from Astellas Pharma (Ibaraki, Japan). A basal diet (BD)
was prepared containing 22% protein, 6% fat, and 47% carbohydrate. A diet enriched in fat
(40% kcal, Primex partially hydrogenated vegetable oil shortening), fructose (22% by weight),
and cholesterol (2% by weight) (catalog number D09100301; Research Diets, New Brunswick,
NJ, USA) was purchased. Clapper et al. [27] reported that this diet (the AMLN diet) induces all
stages of NAFLD for periods>20 weeks in C57BL/6J mice. The diet D09100301 with 40 mg
ipragliflozin L-proline/kg of diet (D14101901; Research Diets) was purchased.
Animal experiments
This study was in accordance with the Guidelines for the Care and Use of Laboratory Animals
set by Yokohama City University Medical School (Yokohama, Japan). The protocol was
approved by the Committee on the Ethics of Animal Experiments of the University of Yoko-
hama City University Medical School (Permit Number: F-A-15-016). All surgery was performed
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BD, basal diet; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; FFA, free fatty acid;
HOMA-IR, homeostasis model assessment of insulin
resistance; TG, triglycerides; H&E, hematoxylin and
eosin; MT, Masson’s trichrome; SR, Sirius red; α-
SMA, α-smooth muscle actin; PCR, polymerase
chain reaction; mRNA, messenger RNA; ACC,
acetyl-CoA carboxylase; SREBP1c, sterol regulatory
element-binding protein 1c; PPARα, peroxisome
proliferator activated receptor α; CPT1A, carnitine
palmitoyltransferase 1A; MTTP, microsomal
triglyceride transfer protein.
with sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. The
experimental protocol is outlined in S1 Fig.
Six-week-old male C57BL/6J mice were obtained from CLEA Japan (Tokyo, Japan). After a
2-week acclimatization period, the groups of mice were fed as follows: BD mice fed a BD for 20
weeks, AMLN mice fed D09100301 for 20 weeks, and SGLT2I mice fed D09100301 for 12
weeks followed by D14101901 for 8 weeks. All animals were housed under conventional condi-
tions with controlled temperature, humidity, and light (12-h light–dark cycle) and provided
with food and water.
Biochemical analyses
Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cho-
lesterol, fasting plasma glucose, insulin, and free fatty acids (FFAs) were measured by a local
laboratory (SRL, Tokyo, Japan). As an alternative method for assessment of insulin resistance,
the homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the
following formula:
HOMA‐IR ¼ insulin ðmU=mLÞ  fasting plasma glucose ðmg=dLÞ=405:
Levels of triglycerides (TGs) and FFAs in total lipid extracts of the liver were determined by
colorimetric assays (Wako Pure Chemical Industries, Osaka, Japan).
Histological and immunohistochemical analyses
Paraffin-embedded sections were stained with hematoxylin and eosin (H&E), Masson’s tri-
chrome (MT) or Sirius red (SR). For lipid staining, frozen sections were stained with oil red O
and counterstained with hematoxylin. The NAFLD activity score and fibrosis stage were scored
by an outsourcing company (Allisere, Tokyo, Japan) in a blind manner according to the
method of Kleiner et al. (S1 Table) [27]. Immunohistochemistry was carried out on cryostat
liver sections (thickness, 7 μm). Sections were incubated with primary antibodies and stained
with Alexa Fluor-conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA,
USA). Apoptosis was assessed by TUNEL staining of paraffin-embedded slides. Images of five
random fields of each section were selected and the number of apoptotic cells per field was
counted. To quantify the area of SR staining and α-smooth muscle actin (α-SMA) staining,
images of five random fields of each section were processed with Photoshop Elements v13
(Adobe Systems, San Jose, CA, USA). Each value was expressed as the percentage of the total
area of the section.
RNA isolation and real-time polymerase chain reaction (PCR) analyses
Total RNA was extracted from samples of liver tissue using an RNeasy mini kit (Qiagen,
Tokyo, Japan). Messenger RNA (mRNA) of murine α-SMA, collagen 1α1, acetyl-CoA carbox-
ylase (ACC), sterol regulatory element-binding protein 1c (SREBP1c), peroxisome proliferator
activated receptor α (PPARα), carnitine palmitoyltransferase 1A (CPT1A), microsomal triglyc-
eride transfer protein (MTTP), and β-actin were determined in liver tissue using a fluores-
cence-based reverse transcription-PCR and an ABI PRISM 7700 Sequence Detection System
(Life Technologies, Carlsbad, CA, USA). SREBP1c and ACC1 are key factors of lipid synthesis
[28]. PPARα is a key factor for hepatic lipid metabolism because it stimulates the transcription
of PPARα-regulated genes [29, 30]. CPT-1 is a key regulatory enzyme of β-oxidation and is
required for the transport of long-chain fatty acids into mitochondria [31]. MTTP has a pivotal
role in export of very-low-density lipoprotein from the liver [32].
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Statistical analyses
Data were recorded as mean ± standard deviation (SD). Differences between the two groups
were assessed using the Student’s t-test and p<0.05 was considered significant. Statistical anal-
yses were carried out using JMP v11.2.0 (SAS Institute, Cary, NC, USA).
Results
Effect of ipragliflozin on physical, biochemical, and pathological
parameters in model mice
Table 1 shows the characteristics of the model mice. There were no differences in daily food
intake among the three groups. AMLN mice exhibited obesity, insulin resistance, and liver
injury in comparison with BD mice. No difference in body weight and weight of epididymal
adipose tissue between AMLNmice and SGLT2I mice was observed, but liver weight was sig-
nificantly lower in SGLT2I mice compared with AMLN mice. SGLT2I mice showed lower lev-
els of total cholesterol than AMLN mice. Ipragliflozin reduced the levels of fasting plasma
glucose and insulin, and improved insulin resistance significantly in SGLT2I mice. Levels of
aminotransferase and FFAs were decreased significantly in SGLT2I mice. Only one AMLN
mouse showed hepatocyte ballooning, but AMLN mice were affected by steatosis, inflamma-
tion, and fibrosis in the liver according to pathological evaluations (Table 2).
Ipragliflozin improved the pathogenesis of NASH in mice
The steatosis grade was significantly lower in SGLT2I mice than in AMLN mice (Table 2).
Staining (H&E, oil red O) showed that the livers of SGLT2I mice had fewer and smaller lipid
droplets in the peripheral periportal zone in comparison with AMLN mice (Fig 1A and 1B).
Ipragliflozin reduced TG and FFA content in the livers of SGLT2I mice (Fig 1C). Ipragliflozin
improved liver injury in SGLT2I mice significantly (Table 1) and also decreased the lobular
inflammation grade significantly (Table 2). Hepatocyte apoptosis is a key pathological feature
of NASH and is associated with progressive inflammation and fibrosis of the liver [33, 34]. The
Table 1. Characteristics of model mice.
Parameters BD AMLN SGLT2I
Food intake (g/day) 3.41±0.13 3.46±0.13 3.58±0.21
Body weight (g) 28.9±1.4 39.7±2.8* 39.6±1.1*
Liver weight (g) 1.26±0.10 3.32±0.37* 2.77±0.42*†
Weight of epididymal adipose tissue (g) 0.23±0.08 1.09±0.18* 1.10±0.10*
Fasting plasma glucose (mg/dL) 90.7±32.2 203.5±55.2* 142.4±41.6*†
Insulin (ng/mL) 0.32±0.26 1.13±0.56* 0.48±0.26†
HOMA-IR 1.96±2.0 15.5±9.7* 4.8±3.3†
Total cholesterol (mg/dL) 97.7±5.4 270.1±47.1* 200.2±23.8*†
AST (IU/L) 40.5±8.1 400.4±136.1* 194.0±114.6*†
ALT (IU/L) 26.5±15.0 471.9±149.0* 178.8±122.2*†
Free fatty acid (uEQ/L) 938±293.1 1325.4±140.8* 1154.2±106.9†
HOMA-IR, the homeostasis model assessment of insulin resistance; AST, aspartate aminotransferase;
ALT, alanine aminotransferase. Data are the mean ± SD (n = 5–8). Signiﬁcance was determined using the
Student’s t-test:
* p<0.05 versus BD mice
† p<0.05 versus AMLN mice
doi:10.1371/journal.pone.0146337.t001
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number of apoptotic cells in SGLT2I mice was fewer than that in AMLN mice (Fig 2). The
extent of fibrosis was confirmed by staining (MT, SR, α-SMA) and by mRNA expression of col-
lagen 1α1 and α-SMA. MT staining revealed that AMLN mice developed liver fibrosis (Fig
3A), but the fibrosis stage was significantly lower in SGLT2I mice than in AMLN mice
(Table 2). In SGLT2I mice, areas of SR staining were significantly smaller than those in AMLN
mice (Fig 3B). Furthermore, mRNA levels of collagen 1α1 and α-SMA in SGLT2I mice were
significantly lower than those in AMLN mice (Fig 3C). The α-SMA staining and the areas of α-
SMA staining were also smaller in SGLT2I mice than in AMLN mice (Fig 3D).
Ipragliflozin accelerated lipid outflow from the liver in mice
We analyzed mRNA expression of ACC1, SREBP1c, PPARα, CPT1A, and MTTP in the liver.
The mRNA expressions of ACC1 and SREBP1c are markers of lipid inflow in the liver, while
mRNA expressions of PPARα, CPT1A, and MTTP are markers of lipid outflow in the liver.
The mRNA expressions of ACC1, SREBP1c, PPARα, CPT1A, and MTTP in AMLN mice and
SGLT2I mice were lower than those of BD mice, but mRNA expressions of PPARα, CPT1a,
and MTTP in SGLT2I mice were significantly higher than those in AMLNmice (Fig 4).
These results suggested that ipragliflozin had a therapeutic effect on NASH by improving
insulin resistance, suppressing hepatocyte apoptosis, and upregulating lipid outflow from the
liver.
Discussion
We investigated the effect of ipragliflozin (selective inhibitor of SGLT2) on NASH in mice. Our
results suggested that ipragliflozin had a therapeutic effect on NASH with T2DM.
NAFLD is the most common chronic disease of the liver worldwide. In general, NAFL is
non-progressive and benign, whereas NASH can progress to cirrhosis and hepatocellular carci-
noma. In terms of pathology, not only liver steatosis but also inflammation and/or fibrosis of
the liver are recognized in NASH. In the present study, we used AMLN, which is a diet-induced
model of NASH. AMLN induces NASH without reliance on genetic mutations, use of toxins,
or nutrient deficiency. An AMLN diet induces all pathological stages of NAFLD for any period
>20 weeks in C57BL/6J mice. AMLN also exhibit obesity and insulin resistance [26].
In the present study, AMLN mice showed steatosis, inflammation, and fibrosis of the liver,
as well as obesity and insulin resistance (Tables 1 and 2). Thus, AMLN has similar biochemical
and pathological characteristics to that of human NASH. These characteristics are not observed
Table 2. Liver pathology scores.
Parameter BD AMLN SGLT2I
Steatosis 0 3.0* 2.4±0.6*†
Lobular Inﬂammation 0 1.8±0.8* 0.8±0.8*†
Hepatocyte Ballooning 0 0.2±0.4 0
NAS 0 5.0±0.7* 3.2±0.8*†
Fibrosis stage 0 1.6±0.5* 0.8±0.4*†
NAFLD activity score (NAS) and ﬁbrosis stage were scored according to the method described by Kleiner
et al. [27], as outlined in S1 Table. NAS, NAFLD Activity Score. Data are the mean ± SD (n = 5 each).
Signiﬁcance was determined using the Student’s t-test:
* p<0.05 versus BD mice
† p<0.05 versus AMLN mice
doi:10.1371/journal.pone.0146337.t002
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Fig 1. Ipragliflozin improved steatosis and decreased lipid content in the liver. (A) Liver sections from BDmice, AMLNmice and SGLT2I mice.
Hematoxylin and eosin (H&E) staining, (B) oil red O staining. Magnification, 200×. Scale bars: 200 μm. (C) Triglyceride (TG) and free fatty acid (FFA) content
was measured in the livers of BD, AMLN, and SGLT2I mice (n = 4–6). Results are the mean ± SD. Significance was tested using the Student’s t-test
(*p<0.05).
doi:10.1371/journal.pone.0146337.g001
Fig 2. Ipragliflozin improved liver inflammation and suppressed hepatocyte apoptosis. TUNEL-stained paraffin-embedded sections of liver tissue from
BD, AMLN, and SGLT2I mice. Magnification, 400×. Scale bars: 100 μm. The number of apoptotic cells per field was counted in BD, AMLN, and SGLT2I mice
(n = 5–8). Results are the mean ± SD. Significance was determined using the Student’s t-test (*p<0.05).
doi:10.1371/journal.pone.0146337.g002
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in streptozotocin–nicotinamide-induced T2DMmice fed a high-fat diet or mice fed a CDAA
diet.
First-line treatment for NAFLD is lifestyle intervention to achieve weight reduction [35].
However, efficacious drugs approved for NAFLD treatment are lacking. Metformin and
Fig 3. Ipragliflozin improved fibrosis. (A) Liver sections from BD, AMLN and SGLT2I mice. Masson’s trichrome (MT), (B) Sirius red (SR) staining. Areas of
SR staining in the liver of BD, AMLN, and SGLT2I mice (n = 5–8). (C) Expression of collagen 1α1 mRNA, and α-smooth muscle actin α (α-SMA) mRNA in BD,
AMLN, and SGLT2I mice (n = 5–8). (D) α-SMA-stained paraffin-embedded sections of liver tissue from BD, AMLN, and SGLT2I mice. Areas of α-SMA
staining in the livers of BD, AMLN, and SGLT2I mice (n = 5–8). Magnification, 200×. Scale bars: 200 μm. Results are the mean ± SD. Significance was
determined using the Student’s t-test (*p<0.05).
doi:10.1371/journal.pone.0146337.g003
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pioglitazone are insulin-sensitizing agents. In a meta-analysis, metformin with lifestyle inter-
vention did not improve aminotransferase levels and liver histology compared with lifestyle
intervention alone [36]. Pioglitazone has beneficial effects on NASH, but there are problems in
terms of long-term efficiency and safety, such as association with the side effects of cardiovas-
cular disease, congestive heart failure, bladder cancer, and bone loss [37, 38].
SGLT2Is have been developed for T2DM treatment but are expected to have therapeutic
effects on NASH. Given the mechanism of action of SGLT2Is, urinary tract and genital infec-
tions are considered as side effects. However, Vivian et al. [18] reported that no safety concerns
were identified in a 12-week treatment study. SGLT2Is have been shown to decrease amino-
transferase levels in T2DM patients [39]. Ipragliflozin has been demonstrated to improve liver
steatosis in T2DMmice [21]. However, whether SGLT2Is have potential effects on NASH are
not known. Therefore, we investigated the effect of ipragliflozin on NASH in AMLNmice.
A scheme illustrating the effects of ipragliflozin on NASH in our study is shown in Fig 5.
Ipragliflozin improves hyperglycemia by inducing urinary excretion of glucose. The ipragliflo-
zin dose dependently increases urinary glucose excretion in various types of mice such as
normal and streptozotocin–nicotinamide-induced diabetic mice [20–23]. In this study, we con-
sidered that ipragliflozin improved insulin resistance by increasing urinary glucose excretion.
Insulin resistance is a key factor affecting liver steatosis [40, 41]. In the insulin-resistant
state, serum concentrations of FFAs are elevated [42] and have an important role in liver stea-
tosis [43]. In the present study, ipragliflozin ameliorated liver steatosis by improving insulin
resistance and decreasing FFA levels (Tables 1, 2 and Fig 1).
It is thought that the pathogenesis of NASH involves lipotoxicity, gut/nutrient-derived sig-
nals, adipocytokines, and genetic factors [44]. Lipotoxicity is excess accumulation of lipids in
non-adipose tissues and is caused by an increase in the flux of FFAs within hepatocytes [45,
46]. Previous reports showed that lipotoxicity leads to cellular injury and death and that this is
one of the key factors of inflammation and fibrosis [47–49]. Recent studies have suggested that
Fig 4. Ipragliflozin accelerated β-oxidation and export of very-low-density lipoprotein. Expression of mRNA of acetyl-CoA carboxylase (ACC), sterol
regulatory element-binding protein 1c (SREBP1c), peroxisome proliferator activated receptor α (PPARα), carnitine palmitoyltransferase 1A (CPT1A), and
microsomal triglyceride transfer protein (MTTP) in BD, AMLN, and SGLT2I mice (n = 5–8). Results are the mean ± SD. Significance was determined using
the Student’s t-test (*p<0.05).
doi:10.1371/journal.pone.0146337.g004
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hepatocyte apoptosis induced by FFAs is important in the pathogenesis of NASH [50]. Previ-
ously, we reported that a reduction in β-oxidation, and the blockade of export of very-low-den-
sity lipoprotein, are key factors in the pathogenesis of NASH [51], and therefore, this report is
considered to confirm the theory of lipotoxicity. In the present study, ipragliflozin improved
the lobular inflammation score and the number of apoptotic cells by reducing hepatic levels of
FFAs (Table 2, Figs 1 and 2). In SGLT2I mice, β-oxidation and export of very-low-density lipo-
protein were accelerated by upregulation of expression of PPARα, CPT1A, and MTTP genes
(Fig 3). It is thought that these genes are negatively regulated if systemic inflammation (e.g.,
insulin resistance) is present [52–54]. SGLT2I mice showed increased outflow of lipids from
the liver because ipragliflozin improved insulin resistance and liver inflammation. Hence, we
hypothesize that ipragliflozin improved insulin resistance and lipotoxicity and as a result, it
decreased liver inflammation and hepatocyte apoptosis. Liver fibrosis is a marker for the pro-
gression of liver disease. Ipragliflozin decreased areas of SR staining and α-SMA staining, and
lowered mRNA levels of collagen 1α1 and α-SMA (Fig 3). Our results suggest that ipragliflozin
improves insulin resistance and indirectly affects the pathogenesis of NASH.
Hayashizaki-Someya et al. reported that ipragliflozin has a prophylactic effect on hepatic
steatosis and fibrosis in rats fed a CDAA diet [24]. Although CDAA-diet rat model is a nutrient
deficiency model and there are few different clinical conditions between that model and
human NASH, ipragliflozin suppressed both hepatic steatosis and fibrosis. Ipragliflozin may
directly affect NASH pathogenesis regardless of improvement of insulin resistance, when we
consider this results.
Fig 5. Mechanism of the effect of ipragliflozin on NASH in AMLN and SGLT2I mice (schematic). TGs, triglycerides; FFAs, free fatty acids.
doi:10.1371/journal.pone.0146337.g005
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Obesity is strongly associated with NAFLD. In the obese population, it has been reported
that>74% have NAFLD [9]. Other reports have shown that ipragliflozin decreases body
weight and the weight of epididymal adipose tissue in mice [21, 23]. In T2DM patients, a selec-
tive inhibitor of SGLT2, dapagliflozin, has been shown to reduce body weight [55]. Yokono
et al. [23] reported that the mean daily intake of food was slightly greater in ipragliflozin-
treated rats fed a high-fat diet. In the present study, although there was no difference in daily
food intake, it was slightly greater than AMLN mice in SGLT2I mice. Ipragliflozin decreased
liver weight significantly, but body weight and weight of epididymal adipose tissue were com-
parable (Table 1). We hypothesize that this discrepancy occurred due to differences in food
intake, protocols or strains of mice. Although there was no difference in body weight, it is a sur-
prising result that in SGLT2I mice, the clinical and pathological conditions were improved in
comparison with the AMLN mice.
This study had three main limitations. First, we used just one dose of ipragliflozin. D14101901
was the AMLN diet with 40 mg ipragliflozin L-proline/kg of diet. This dose is 3 mg/kg/day and
similar to a clinical dose of 50 mg. Second, we administered ipragliflozin only, so anti-DM drugs
could not be compared with ipragliflozin. Third, although we fed C57BL/6J mice with an AMLN
diet for 20 weeks, only one AMLNmouse showed hepatocyte ballooning.
In summary, we showed that ipragliflozin improved the pathogenesis of NASH by improv-
ing insulin resistance and lipotoxicity in NASH-model mice with T2DM. These results suggest
a therapeutic effect of ipragliflozin on NASH with T2DM.
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